In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Derrick Gingery

Senior Writer

Washington, DC

Derrick focuses on the US FDA user fee programs, regulations and policy for new and generic drugs, biologics and biosimilars, advisory committee and other agency activities, as well as federal legislation and budget matters on Capitol Hill. He also hosts Pink Sheet's Pharma Regulatory Podcast. An award-winning journalist, Derrick has been a reporter for several community newspapers and a business journal. When not following FDA, Derrick is keeping close tabs on Indiana University basketball.

Latest From Derrick Gingery

China Rhetoric Could Be Key To US FDA IT System Upgrade

FDA Commissioner Robert Califf says mentioning China helps increase congressional support.

Cybersecurity China

US FDA Oncology, Device Centers Developing Public Diagnostic Standards

Pilot program would get around the ‘one drug, one test’ policy, which has created intellectual property issues.

Cancer Diagnostics

AAM CEO Leonard Departs After Two Years, Creating Another Trade Group Searching For New Leader

David Gaugh, AAM’s executive VP of sciences and regulatory affairs, was named the interim CEO, making him the fourth person to run the association since February 2020.

Generic Drugs Leadership

To Prevent Shortages, US FDA Wants Notices From Drug Firms On Spikes In Demand

Demand-related shortages are a relatively new problem, but FDA maintains its tools can prevent or end them.

Supply Chain OTC Drugs

To Prevent Shortages, US FDA Wants Sponsor To Provide Notifications Of Demand Spike

Demand-related shortages are a relatively new problem, but the FDA maintains their tools can prevent or end them.

Supply Chain Manufacturing

US FDA Says Confirmatory Trials Should Start Before Accelerated Approval But Is Not ‘Dogmatic’

Beginning confirmatory trials before the accelerated approval is granted shortens the time between clearance and the confirmation of benefit, when patients are at risk, said Oncology Center of Excellence Director Richard Pazdur.

Clinical Trials Review Pathway
See All
UsernamePublicRestriction

Register